Rocket Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

• Rocket Pharmaceuticals Inc RCKT.OQ reported a quarterly adjusted loss of 56 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -66 cents. The mean expectation of fifteen analysts for the quarter was for a loss of 61 cents per share. Wall Street expected results to range from -82 cents to -50 cents per share.

• Reported revenue was zero​; analysts expected $1.86 million.

• Rocket Pharmaceuticals Inc's reported EPS for the quarter was a loss of 56 cents​.

• The company reported a quarterly loss of $61.33 million.

• Rocket Pharmaceuticals Inc shares had risen by 0.4% this quarter and lost 46.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 12.2% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Rocket Pharmaceuticals Inc is $36.00

This summary was machine generated from LSEG data May 8 at 08:22 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)